Atsuko Yano‐Takamori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Atsuko Yano‐Takamori has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Sugiyama
Department of Allergology, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan
1 shared publication Haruko Nishie
Department of Dermatology NHO Fukuoka National Hospital Fukuoka Japan
1 shared publicationKaoru Kojima
Department of Clinical Research NHO Fukuoka National Hospital Fukuoka Japan
1 shared publicationMiku Nishimura
Department of Dermatology NHO Fukuoka National Hospital Fukuoka Japan
1 shared publicationTakeshi Nakahara
Department of Dermatology, Graduate School of Medical Science Kyushu University Fukuoka Japan
1 shared publicationTetsuya Hiramoto
Department of Clinical Research NHO Fukuoka National Hospital Fukuoka Japan
1 shared publication
Latest Publications
- 16 January 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (4) , 740-743
Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events
Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab. We also found that the score of excoriation on the trunk tended to be higher. These results indicate that patients with mild severity of eruptions on the trunk at initiation could be suitable for nemolizumab therapy, with the potential for long‐term continuation with the control of cAEs.
- 16 January 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (4) , 740-743
Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events
Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab. We also found that the score of excoriation on the trunk tended to be higher. These results indicate that patients with mild severity of eruptions on the trunk at initiation could be suitable for nemolizumab therapy, with the potential for long‐term continuation with the control of cAEs.